Home/Biosimilar Atlas/Companies/Sam Chun Dang Pharm

Sam Chun Dang Pharm

Biosimilar developer, South Korea. 1 development product across 1 molecule: aflibercept.

First approval in the Atlas: Aug 2025, Eiyzey, aflibercept (EMA)
FDAproducts approved0
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved1
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product3 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AfliberceptEiyzey / Vgenfli SCD411·Aug 2025MHRASep 2025···3/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists one comparative trial sponsored by Sam Chun Dang Pharm for one molecule: aflibercept. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
AfliberceptSCD411Sam Chun Dang PharmEyleaPhase 3Comparative efficacyCompletedAug 2020Sep 2022Eiyzey / VgenfliNCT04480463

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Sam Chun Dang Pharm, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AlteogenOne shared molecule: aflibercept1 molecule in its portfolioAlvotechOne shared molecule: aflibercept5 molecules in its portfolioAmgenOne shared molecule: aflibercept8 molecules in its portfolioApotexOne shared molecule: aflibercept3 molecules in its portfolioBiocon BiologicsOne shared molecule: aflibercept9 molecules in its portfolioCelltrionOne shared molecule: aflibercept10 molecules in its portfolio

Chronology

Compare Sam Chun Dang Pharm with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.